Compare stocks

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.